Location
ul. Związkowa 26, 20-148 LUBLIN, PL
Our hours
8:00 AM – 17.00 PM
Monday – Friday
Contact us
e-mail: office@iamelli.com
ELLI mantra
Simply
Clinical Trials
ELLI makes clinical trials easier and cheaper by helping patients take their medication on time.
ELLI makes clinical trials easier and cheaper by helping patients take their meds on time.
COST OF NON COMPLIANCE
Falsified reporting
Patients falsify reporting of drug intake due to psychological reasons.
NonCompliance
Even 40% of patients stop adhering to drug therapy in first 150 days of trial.
Cost Impact of NonCompliance
Delayed drug market entry can cost from £450K up to £6 mil per day! Extra patient enrollment can cost up to £4 mil per trial.
Increased data credibility
ELLI devices monitor patients’ drug intake.
Data of drug intake flows directly into the ELLI platform in real time, eliminating falsified data provided by patients.
Know exactly when a patient :
- took a dose
- missed a dose
- tried to manipulate/open the device
Acceleration of the Trial:
Higher rates of compliance:
Patients that know they are being monitored
comply with the medication regimen.
Automatic & manual reminders:
The device itself reminds patients to take drugs
on time.
If patient is still forgetful, give him a call, minutes
after skipping a dose.
Faster elimination of noncomplying patients:
Thanks to real time data inflow you may quickly
remove chronically noncomplying patients.
Reduction of Trial cost:
Due to constant real time monitoring and ease of use, patient compliance increases causing:
- Savings on recruitment costs
- Earlier market entry of drug
meet THE FOUNDERS
Our Team
Marcin Masek
Co-Founder
The techie and leader
Rafał Stasieńko
Co-Founder
The rainmaker
Hanna Masek
Co-Founder
The Medical expert
join the team
Work with us
If You are passionate about changing the pharma industry let us know. You might just fit in. No matter your gender, race, age, experience or education. We choose people for their future not their past.
The ELLI team is inclusive…
“Drugs don't work in patients who don't take them.”
C. Everett Koop, M.D.